Brief: Verrica Pharmaceuticals Begins Patient Dosing In Part 2 Of Mid-stage Cancer Study

Verrica Pharmaceuticals

12/04/2023 12:56

April 12 (Reuters) - Verrica Pharmaceuticals Inc
 VRCA.O :
    * VERRICA PHARMACEUTICALS ANNOUNCES DOSING OF THE FIRST
PATIENT IN
PART 2 OF PHASE 2 STUDY EVALUATING VP-315 FOR THE TREATMENT OF
BASAL CELL CARCINOMA
    * VERRICA PHARMACEUTICALS ANNOUNCES DOSING OF THE FIRST
PATIENT IN
PART 2 OF PHASE 2 STUDY EVALUATING VP-315 FOR THE TREATMENT OF
BASAL CELL CARCINOMA

Source text for Eikon:  ID:nGNX1zqGrg 
Further company coverage:  VRCA.O 

 ((Reuters.Briefs@thomsonreuters.com;))